Welcome to our dedicated page for 60 degrees pharmaceuticals news (Ticker: SXTP), a resource for investors and traders seeking the latest updates and insights on 60 degrees pharmaceuticals stock.
60 Degrees Pharmaceuticals, Inc. (SXTP) is a clinical-stage company advancing novel therapies for infectious diseases, including its FDA-approved malaria prophylaxis ARAKODA. This news hub provides investors and healthcare stakeholders with verified updates on the company's scientific progress and operational developments.
Access timely announcements including clinical trial results, regulatory milestones, research partnerships, and strategic initiatives. Our curated collection ensures transparent tracking of SXTP's work in malaria prevention, tick-borne illness therapies, and antifungal/viral treatment pipelines.
Key updates cover FDA communications, trial phase transitions, academic collaborations, and market expansion efforts. The resource is particularly valuable for monitoring the company's progress in repurposing tafenoquine for emerging indications like babesiosis.
Bookmark this page for centralized access to SXTP's latest scientific advancements and corporate announcements. For comprehensive tracking of infectious disease treatment innovations, consider subscribing to our regulatory update alerts.
60 Degrees Pharmaceuticals (NASDAQ:SXTP) has announced the pricing of a $5 million public offering with potential additional proceeds of up to $5 million through warrant exercises. The offering consists of 2,631,578 shares of common stock (or pre-funded warrants) at $1.90 per share, along with Series A-1 and A-2 warrants.
The offering includes Series A-1 warrants with a 5-year term and Series A-2 warrants with an 18-month term, both with an exercise price of $1.90 per share. H.C. Wainwright & Co. is serving as the exclusive placement agent, with closing expected around July 16, 2025. The company plans to use proceeds for working capital and general corporate purposes.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has announced the potential market size for ARAKODA® (tafenoquine) in treating human babesiosis, projecting maximum annual sales of $245 million and a cumulative market value of $1.1 billion through patent expiration in 2035.
The market assessment is based on comprehensive research including a 6,000-patient nationwide survey and feedback from 300 healthcare professionals. The company estimates a total addressable market of 380,000 patients annually.
Currently, three clinical trials are underway or planned to evaluate tafenoquine's safety and efficacy. The company expects to submit a New Drug Application (NDA) to the FDA in 2026, pending positive trial results.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) announced plans to submit a Minor Use Minor Species (MUMS) designation request to the FDA for tafenoquine to treat acute canine babesiosis in 2025. The submission will be supported by three clinical efficacy studies that evaluated ARAKODA® (tafenoquine) for canine babesiosis, including one company-sponsored study at North Carolina State University.
The studies demonstrated that tafenoquine was well-tolerated and effective in treating both experimental and naturally acquired Babesia infections in dogs. This development is significant as there are currently no FDA-approved oral treatments for canine babesiosis, an emerging tick-borne illness that affects hundreds to thousands of dogs annually in the United States.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has reported its Q1 2025 financial results, showing mixed performance. The company's net product revenues increased 55% year-over-year to $163.6 thousand, primarily driven by domestic sales of ARAKODA®. Gross profit saw significant growth of 124%, reaching $90.3 thousand compared to $40.2 thousand in Q1 2024.
However, operating expenses rose to $2.09 million from $1.41 million in the previous year, with $535.4 thousand attributed to increased sales, investor-related services, and stock-based compensation. The company reported a net loss of $2.01 million ($1.56 per share) in Q1 2025, compared to a net income of $308.7 thousand ($1.83 per share) in Q1 2024, largely due to a $1.74 million change in fair value of derivative liabilities.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reveals groundbreaking survey results suggesting babesiosis disease burden in the US is significantly higher than CDC estimates. The survey, conducted among 6,000 US adults, found that 1.26% of respondents (equivalent to ~3 million people) reported receiving a babesiosis diagnosis in their lifetime, compared to CDC's 1,834 reported cases in 2020.
The study indicates that approximately 17% of babesiosis patients experienced illness lasting six months or more, suggesting around 570,000 US adults have faced chronic disease. Additionally, 3.7% of respondents (~9.9 million Americans) reported experiencing chronic fatigue lasting longer than six months, with 56% of these individuals having received a formal Chronic Fatigue Syndrome diagnosis.
This significant disparity between survey findings and CDC statistics suggests babesiosis may be substantially underdiagnosed or underreported, potentially indicating a larger market for effective treatments.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) CEO Geoff Dow will participate in the Healing Lyme Summit from April 15-21, 2025, to discuss babesiosis, a tick-borne disease commonly occurring alongside Lyme disease. Dr. Dow will address the increasing prevalence of babesiosis in the United States, clinical challenges, and the need for better diagnostic and treatment options.
The company is currently conducting two clinical trials (NCT06207370 and NCT06478641) evaluating tafenoquine for treating severe babesiosis and persistent disease in immunosuppressed patients. The summit is a free virtual event featuring scientific discussions and educational content on tick-borne illnesses.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has signed a Patent License Agreement with Yale School of Medicine and Yale School of Public Health to advance the development and commercialization of tafenoquine for babesiosis treatment and prevention.
The agreement follows collaborative research between the organizations studying tafenoquine's activity against babesiosis, a tick-borne disease that infects red blood cells. Currently, tafenoquine is not FDA-approved for babesiosis treatment and prevention.
If approved, tafenoquine could address a significant unmet medical need, particularly for patients who progress beyond initial mild symptoms. The drug could potentially become the first prophylaxis available for babesiosis. According to Dr. Peter James Krause from Yale, relapsing babesiosis in immunocompromised patients has an estimated mortality rate of 20 percent and is challenging to treat.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported significant financial growth for FY 2024. Net product revenues increased 140% to $607.6 thousand, driven by domestic sales of ARAKODA®. The company achieved a gross profit of $222.8 thousand in 2024, compared to a $221 thousand loss in 2023.
Operating expenses rose to $10.0 million in 2024 from $4.9 million in 2023, primarily due to non-recurring R&D charges and babesiosis clinical trial costs. Net loss widened to $8.43 million ($18.55 per share) from $3.925 million ($59.18 per share) in 2023.
Key developments include:
- FDA approval to import Kodatef® (Australian equivalent of Arakoda) due to increased U.S. demand
- Ongoing babesiosis clinical trials with interim analysis expected in Q1 2026
- Additional Arakoda supply lots scheduled for release in early Q2 2025
- Expansion of clinical studies for babesiosis treatment in various patient groups
FAQ
What is the current stock price of 60 degrees pharmaceuticals (SXTP)?
What is the market cap of 60 degrees pharmaceuticals (SXTP)?
